Creative Biolabs is a leading service provider that focuses on antibody discovery and production for various applications. Now, we introduce our high-quality IVD (in vitro diagnostic) antibody and immunoassay development services to global clients. Our services target a wide range of disease biomarkers with diagnostic or prognostic potential, such as the MYC marker.
MYC (c-MYC), like its family members N-MYC and L-MYC, is a transcription factor that regulates pathways underlying cell growth, cell-cycle progression, metabolism, survival, and altering gene expression. It was first discovered as a cellular homolog of the retroviral v-Myc oncogene that was found to induce tumorigenesis in birds. Also, as one of the most frequently amplified oncogene, MYC is aberrantly overexpressed in over half of human cancers. Dysregulations of MYC, such as amplification, chromosome translocation, or loss of upstream repressors, have been found in many human cancers. Furthermore, MYC can activate many genes that are involved in numerous cellular processes, including transcription, translation, chromatin modification, and protein degradation.
Fig.1 The interaction between c-Myc and main proliferative signaling pathways in pancreatic cancer.1
MYC was one of the first oncogenes identified and its overexpression at the RNA and protein levels has subsequently been linked to a wide range of human cancers. There is data showing that the overexpression of MYC protein or the gene has been shown in 80% of breast cancers, 70% of colon cancers, 90% of gynecological cancers, 50% of hepatocellular carcinomas, and a variety of hematological tumors. Toon et al. (2014) reported that MYC protein expression as determined by immunohistochemistry can be used to predict overall survival in patients with colorectal carcinoma undergoing surgical resection. Shi et al. (2019) detected the plasma level of C-MYC by quantitative real-time PCR and the level of MYC protein in breast cancer tissues by immunohistochemistry. The results indicated that plasma C-MYC level might be a potential indicator in the progression of breast cancer.
Creative Biolabs has extensive experience in contract IVD antibody & immunoassay development. We offer customized solutions for developing assays for the quantitative or qualitative detection of different biomarkers, proteins, enzymes, antibodies, metabolites, etc. We offer expertise in different phases of the kit development, including antigen design, antibody generation, recombinant protein expression, and assay development, validation, and production. For more information, please click the links below:
Please feel free to contact us to learn more about what we offer and how to get started on your next project.
References
For Research Use Only.
